Literature DB >> 22025739

Conventional and advanced magnetic resonance imaging in tumefactive demyelination.

Jitender Saini1, Somenath Chatterjee, Bejoy Thomas, Chandrasekharan Kesavadas.   

Abstract

BACKGROUND: Tumefactive demyelination (TD) is a relatively uncommon entity which mimics other focal intracranial lesions. Conventional radiological findings in tumefactive demyelination have been well described. However, DTI and MRS findings in TD have not been studied in detail.
PURPOSE: To evaluate the usefulness of conventional magnetic resonance imaging (MRI), multivoxel 1H spectroscopy (MRS) and diffusion tensor imaging (DTI) in diagnosis and follow-up of TD of the brain.
MATERIAL AND METHODS: Clinical and imaging findings of 18 patients were reviewed. MR imaging data which included conventional imaging as well as MRS and DTI were reviewed. At TE 135ms MRS various metabolite ratios were calculated at different depths of the demyelinating lesions. At TE 30 ms, glutamate-glutamine (GLX-2.1-2.5 ppm) was compared in the lesion to the contralateral normal side. DTI data were available for 15 patients and Dav (mean diffusivity) and trace values were recorded from central and peripheral layers of the index lesion. Histopathological (9 patients) and therapeutic response (9 patients) on follow-up imaging were taken as the diagnostic criterion. In addition, the follow-up MRI scans available were also reviewed.
RESULTS: Characteristic peripheral 'broken ring' type of contrast enhancement was noted in 12 cases. Two or three concentric distinct zones were noted on imaging with distinct metabolic and structural signature in most cases. On TE 135ms, the central part showed variable Choline (Cho) and significantly low N-Acetyl Aspartate (NAA). DTI demonstrated high Dav and very low trace value in this zone. The intermediate area showed higher Cho and lower NAA compared to contralateral normal side. The outermost layer, which corresponded to the contrast enhancing areas on MRI, showed high Cho, lower NAA, and restricted diffusion on DTI. The GLX increase was noted in tumefactive lesions. Lactate was observed in all patients and it appeared higher at the center compared to the periphery of lesions. Follow-up imaging showed shrinkage of index lesions, disappearance of contrast enhancement, and diffusion restriction. MRS showed, persistent abnormalities on follow-up imaging.
CONCLUSION: Tumefactive demyelinating lesions reveal different microstructural changes at different depths of the lesion and this unique feature may be useful in differentiating them from other focal lesions of brain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22025739     DOI: 10.1258/ar.2011.110007

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  13 in total

1.  FREIBURG NEUROPATHOLOGY CASE CONFERENCE: Ring Enhancing Lesion in an Immunocompromised Patient.

Authors:  C A Taschner; O Staszewski; P Reinacher; H Urbach; I Mader; M Prinz
Journal:  Clin Neuroradiol       Date:  2015-09       Impact factor: 3.649

Review 2.  Differential imaging of atypical demyelinating lesions of the central nervous system.

Authors:  Matteo Paoletti; Shaun Ivan Muzic; Francesca Marchetti; Lisa Maria Farina; Stefano Bastianello; Anna Pichiecchio
Journal:  Radiol Med       Date:  2021-01-24       Impact factor: 3.469

3.  Metabolic changes in patients with aneurysmal subarachnoid hemorrhage apart from perfusion deficits: neuronal mitochondrial injury?

Authors:  M Wagner; A Jurcoane; C Hildebrand; E Güresir; H Vatter; F E Zanella; J Berkefeld; U Pilatus; E Hattingen
Journal:  AJNR Am J Neuroradiol       Date:  2013-02-22       Impact factor: 3.825

Review 4.  Metabolic Imaging in Humans.

Authors:  Taylor L Fuss; Leo L Cheng
Journal:  Top Magn Reson Imaging       Date:  2016-10

5.  Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.

Authors:  Rocco Totaro; C Di Carmine; A Splendiani; S Torlone; L Patriarca; C Carrocci; S Sciamanna; C Marini; A Carolei
Journal:  Neurol Sci       Date:  2016-04-15       Impact factor: 3.307

6.  Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis.

Authors:  Mirja Wallner-Blazek; Alex Rovira; Massimo Fillipp; Mara A Rocca; David H Miller; Klaus Schmierer; Jette Frederiksen; Achim Gass; Hugo Gama; Charles P Tilbery; Antonio J Rocha; José Flores; Frederik Barkhof; Alexandra Seewann; Jacqueline Palace; Tarek Yousry; Xavier Montalban; Christian Enzinger; Franz Fazekas
Journal:  J Neurol       Date:  2013-04-26       Impact factor: 4.849

7.  Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.

Authors:  G Balloy; J Pelletier; L Suchet; C Lebrun; M Cohen; P Vermersch; H Zephir; E Duhin; O Gout; R Deschamps; E Le Page; G Edan; P Labauge; C Carra-Dallieres; L Rumbach; E Berger; P Lejeune; P Devos; J-B N'Kendjuo; M Coustans; E Auffray-Calvier; B Daumas-Duport; L Michel; F Lefrere; D A Laplaud; C Brosset; P Derkinderen; J de Seze; S Wiertlewski
Journal:  J Neurol       Date:  2018-07-27       Impact factor: 4.849

Review 8.  Magnetic Resonance Imaging in Multiple Sclerosis.

Authors:  Christopher C Hemond; Rohit Bakshi
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

9.  Combining Diffusion Tensor Metrics and DSC Perfusion Imaging: Can It Improve the Diagnostic Accuracy in Differentiating Tumefactive Demyelination from High-Grade Glioma?

Authors:  S B Hiremath; A Muraleedharan; S Kumar; C Nagesh; C Kesavadas; M Abraham; T R Kapilamoorthy; B Thomas
Journal:  AJNR Am J Neuroradiol       Date:  2017-02-16       Impact factor: 3.825

10.  Clinicoradiologic features distinguish tumefactive multiple sclerosis from CNS neoplasms.

Authors:  Xuling Lin; Wai-Yung Yu; Lishya Liauw; Russell Jude Chander; Weiling E Soon; Hwei Yee Lee; Kevin Tan
Journal:  Neurol Clin Pract       Date:  2017-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.